Establishing a Framework for Global Business Expansion
First written in FY2016. 11 of 18 entries say "Restated". Latest entry: 2026-08-07.
0 other companies' latest entry also says "Restated".
- 2026-08-07RestatedResults
「Overseas, the company is focusing on expanding sales of intravenous indwelling needles by capitalizing on growing global demand, particularly in North America, while also working to expand sales of hemodialysis products and intervention products.」
北米を含む海外需要を捉えた販売拡大方針と、複数品目の海外拡販を再確認している。 - FY2026AdvancedAnnual report
「Overseas, the company is focusing on expanding sales of intravenous indwelling needles by capitalizing on growing global demand, particularly in North America, while also working to expand sales of hemodialysis products and intervention products.」
The company strengthened overseas sales, particularly of indwelling venous needles, by capturing demand outside Japan, including in North America. Overseas sales rose to ¥4,246.055 million from ¥3,521.640 million in the previous fiscal year. - FY2026-H1RestatedAnnual report
「Overseas, the company concluded a sales agreement with 朝日インテック社 in March 2025 for sheath introducers in the European and US markets and is working to expand sales. It has also continued actively promoting dialysis needles and intravenous indwelling needles, which are highly regarded in Japan.」
The company continues its overseas expansion through a sales agreement for sheath introducers in the European and US markets and overseas promotion of dialysis needles and intravenous indwelling needles. - FY2025AdvancedAnnual report
「The company will strengthen overseas sales more than before, focusing on the European and US markets and China.」
The company identified Europe, the United States and China as priority regions for overseas expansion and set out a policy of strengthening sales more than before. It also reported the conclusion of a sales agreement with 朝日インテック社 for sheath introducers for Europe and the United States. - FY2025-H1RestatedAnnual report
「Overseas, intervention products saw lower sales following the end of the sales agreement with Boston Scientific in March 2024, but the company continued active promotion of dialysis needles and intravenous indwelling needles, which are highly regarded in Japan.」
Although intervention product sales declined following the termination of part of the sales agreement, the company continued overseas promotion of dialysis needles and intravenous indwelling needles. - FY2024-Q3RestatedAnnual report
「Overseas sales of dialysis needles, intravenous indwelling needles and sheath introducers, which are highly regarded in Japan, were strong, and the company continued its active promotional efforts.」
The company continues active promotion of strong overseas sales of dialysis needles, intravenous indwelling needles and sheath introducers. - FY2024-Q2RestatedAnnual report
「Overseas sales of dialysis needles, intravenous indwelling needles and sheath introducers, which are highly regarded in Japan, were strong, and the company continued its active promotional efforts.」
The company states that overseas sales of dialysis needles, intravenous indwelling needles and sheath introducers were strong and that promotional activities continued. - FY2024-Q1RestatedAnnual report
「Overseas, the company actively promoted sales and market penetration of dialysis needles, intravenous indwelling needles and sheath introducers, which are highly regarded in Japan.」
The company continues to promote the overseas sales and market penetration of dialysis needles, intravenous indwelling needles and sheath introducers. - FY2023AdvancedAnnual report
「Overseas, the company actively promoted sales and market penetration of dialysis needles, intravenous indwelling needles and sheath introducers, which are highly regarded in Japan. Although this resulted in certain costs in Europe, the company also proceeded with its response to the new MDR regulations. Japan 19,036,651 Overseas 2,570,582 Total 21,607,233」
Overseas sales were ¥2,570.582 million, up from ¥1,955.125 million in the previous fiscal year. The company continued promoting the sales and market penetration of overseas products and addressing the European MDR, indicating measurable progress in global expansion. - FY2023-Q3AdvancedAnnual report
「Going forward, the “Intervention Business” will advance the development of proprietary products specializing in therapeutic fields. In particular, in the field of endovascular treatment for cerebrovascular disease, it will pursue global expansion, both in Japan and overseas, based on products developed by Bolt Medical.」
The company is giving concrete form to its policy of pursuing global expansion in the field of endovascular treatment for cerebrovascular disease, both in Japan and overseas, based on Bolt Medical’s products. - FY2022RestatedAnnual report
「The company regards expanding its overseas business as an important strategic area and is working to strengthen its global development, product and sales capabilities while steadily addressing overseas regulatory requirements.」
The company has reconfirmed its policy of treating overseas expansion as an important strategy and strengthening its development, product and sales capabilities and response to overseas regulatory requirements. - FY2021RestatedAnnual report
「The company regards expanding its overseas business as an important strategic area and is working to strengthen its global development, product and sales capabilities while steadily addressing overseas regulatory requirements.」
The company has reconfirmed its policy of treating overseas expansion as an important strategy and strengthening its development, product and sales capabilities and response to overseas regulatory requirements. - FY2020RestatedAnnual report
「The company regards expanding its overseas business as an important strategic area and is working to strengthen its global development, product and sales capabilities while steadily addressing overseas regulatory requirements.」
The company continues to pursue overseas expansion, strengthen its development, product and sales capabilities, and address overseas regulatory requirements as important strategies. - FY2018AdvancedAnnual report
「The company completed its agreement with a European representative for “HappyCath NEO,” made a CE Mark declaration for the product under the name “Supercath NEO” in fiscal 2017, and launched full-scale expansion in Europe. It will continue working to further expand sales in domestic and overseas dialysis markets.」
Regarding the challenge of establishing a framework with overseas market intelligence and global development, product and sales capabilities, the company reports concrete progress through its agreement with a European representative, CE Mark declaration and launch of European operations. - FY2017AdvancedAnnual report
「The company obtained the CE Mark for “HappyCath NEO” in fiscal 2016. It will now actively pursue expansion in Europe and work to further expand sales in domestic and overseas dialysis markets.」
With “HappyCath NEO” obtaining the CE Mark, the company advanced its European expansion and efforts to expand sales in the dialysis market. - FY2016First statedAnnual report
「Looking ahead to overseas expansion, the company regards establishing a framework capable of tracking trends in overseas markets and equipped with global-level development, product and sales capabilities as a key challenge.」
The company identifies establishing a framework with overseas market intelligence and development, product and sales capabilities as a key challenge.